MANGANCHELATISOMERE

European patent · EP4025259 · In force

Register entry

Publication number
EP4025259
Application number
EP20767545
Kind
European patent with effect for Switzerland and Liechtenstein
Status
In force
Specification
Granted
Filed
Sep 3, 2020
Published
Jul 13, 2022
Granted
Oct 30, 2024
Protection ends at the latest
Sep 2, 2040
Next annual fee due
Sep 30, 2027
IPC classes
A61K 49/10 (2006.01)
C07D 471/08 (2006.01)
C07F 13/00 (2006.01)
Priority
US 201962895121 P 03.09.2019
PCT application
PCT/EP2020/074645 03.09.2020
PCT publication
WO2021/043926 11.03.2021
Filing language
English
Source
Swissreg

History

What the Federal Institute of Intellectual Property published about this title, newest first.

  1. Oct 1, 2026

    Next annual fee due on

    Next annual fee due on
    30.09.2026 → 30.09.2027

    Published in Swissreg on 01.10.2026

  2. Oct 1, 2025

    Next annual fee due on

    Next annual fee due on
    30.09.2025 → 30.09.2026

    Published in Swissreg on 01.10.2025

  3. Sep 10, 2025

    Change

    Published in Swissreg on 10.09.2025

  4. Jan 3, 2025

    Agent entered

    Representative
    Novagraaf International SA, Chemin de l'Echo 3, 1213 Onex

    Published in Swissreg on 03.01.2025

  5. Oct 30, 2024

    Granted

    Specification status
    Non-published patent application → Granted patent
    Status of protective title
    Initiated → Active

    Published in Swissreg on 30.10.2024

Parties

Holder

GE Healthcare AS

Nycoveien 1, 0485 Oslo, NO

Agent

Novagraaf International SA

Chemin de l'Echo 3, 1213 Onex

Inventor

BALES, Brian, C

Niskayuna, New York 12309-1027, US

RISHEL, Michael, James

Niskayuna, New York 12309-1027, US

DINN, Sean, R

Niskayuna, New York 12309-1027, US

The register names each party by name and address. A holder or agent is linked to an organization where exactly one entity of the commercial register bears its name; the street of a party not so recognised is not shown here.